News stories about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.9891438721495 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of CNCE traded down $0.63 during trading hours on Wednesday, reaching $15.07. The company had a trading volume of 1,173 shares, compared to its average volume of 84,778. The company has a market capitalization of $369.26 million, a PE ratio of 3.68 and a beta of 1.00. Concert Pharmaceuticals has a 12-month low of $13.57 and a 12-month high of $30.71.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.05. Concert Pharmaceuticals had a net margin of 67.52% and a negative return on equity of 19.73%. equities analysts forecast that Concert Pharmaceuticals will post -2.08 EPS for the current fiscal year.
A number of brokerages have commented on CNCE. ValuEngine upgraded shares of Concert Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 1st. Mizuho reiterated a “buy” rating and issued a $27.00 price target on shares of Concert Pharmaceuticals in a report on Thursday, August 2nd. HC Wainwright reiterated a “buy” rating on shares of Concert Pharmaceuticals in a report on Friday, August 3rd. Finally, BidaskClub downgraded shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $26.80.
In other news, COO Nancy Stuart sold 31,418 shares of the stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $17.87, for a total value of $561,439.66. Following the completion of the transaction, the chief operating officer now owns 116,085 shares in the company, valued at approximately $2,074,438.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.40% of the company’s stock.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Further Reading: Moving Average (MA)
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.